TAKE A LOOK AT WHICH REPORT YOUR PORTFOLIO'S BEEN MISSING...

Shareholders Foundation offers real-time reporting of class action exposure on a per transaction basis,
including the documents you will need for claim filing and settlement recovery.
Start Monitoring Your Investments

Repros Therapeutics Inc (NASDAQ:RPRX) Investor Investigation Over Potential Breaches Of Fiduciary Duties Announced

  • If you purchased shares of Repros Therapeutics Inc (NASDAQ:RPRX), you have certain options and you should contact the Shareholders Foundation, Inc.

  • To have your information reviewed for options and to receive notifications about this case, please use this form. You may also send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.

Investigation Overview

October 21, 2014 (Update) - On September 26, 2014, Repros Therapeutics Inc announced that it had been granted a Type B Pre-NDA meeting with the FDA in the first half of November, 2014. Repros Therapeutics Inc said that it would seek guidance during this Type B meeting on its planned New Drug Application (NDA) for Androxal for the treatment of secondary hypogonadism with preservation ...



You must register (for free) or login to view the entire investigation.

Click here to Sign In or Register (for a free account)

@screen width:
@theme:
@breakpoints:
@layout: